TY - JOUR
TI - A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
AU - Fadini, G.P.
AU - Tentolouris, N.
AU - Caballero Mateos, I.
AU - Bellido Castañeda, V.
AU - Morales Portillo, C.
JO - Diabetes Therapy
PY - 2020
VL - 11
TODO - 2
SP - 423-436
PB - Adis
SN - 1869-6953, 1869-6961
TODO - 10.1007/s13300-019-00744-6
TODO - acarbose;  albumin;  angiotensin receptor antagonist;  antithrombocytic agent;  beta adrenergic receptor blocking agent;  calcium channel blocking agent;  dapagliflozin;  dipeptidyl peptidase IV inhibitor;  glucagon like peptide 1 receptor agonist;  hemoglobin A1c;  high density lipoprotein;  high density lipoprotein cholesterol;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  insulin;  low density lipoprotein cholesterol;  metformin;  pioglitazone;  sulfonylurea;  triacylglycerol, acute heart infarction;  adult;  aged;  alanine aminotransferase blood level;  Article;  aspartate aminotransferase blood level;  body height;  body mass;  body weight;  cerebrovascular accident;  chronic kidney failure;  comorbidity;  coronary artery atherosclerosis;  diabetes mellitus;  diastolic blood pressure;  estimated glomerular filtration rate;  female;  geographic distribution;  geography;  glucose blood level;  Greece;  heart rate;  human;  Italy;  major clinical study;  male;  non insulin dependent diabetes mellitus;  observational study;  peripheral occlusive artery disease;  prescription;  prevalence;  primary medical care;  priority journal;  retinopathy;  Southern Europe;  Spain;  systolic blood pressure;  total cholesterol level
TODO - Introduction: A real-world study was performed to describe the clinical characteristics of patients who received dapagliflozin to better understand differences when initiating dapagliflozin in various countries and different prescribing settings. Methods: We assessed pooled data from observational studies carried out in Italy (n = 2484), Spain (n = 564) and Greece (n = 87). The primary objective was to compare the clinical profile of patients initiating dapagliflozin in the three countries. We also evaluated the percentage of patients who received dapagliflozin in clinical practice who satisfied DECLARE-TIMI 58 enrolment criteria. Results: In Italy and Spain, around 90% of patients were receiving metformin vs. 66% in Greece (p < 0.0001). Patients in Greece had lower levels of estimated glomerular filtration rate and lower prevalence rates of retinopathy, prior stroke, acute myocardial infarction, peripheral arterial disease and atherosclerotic cardiovascular disease. Grouping the cohorts by prescribing setting (primary vs. specialist care), baseline HbA1c was lower in primary care (8.4 ± 1.7 vs. 8.7 ± 1.5, respectively; p < 0.0001). Significantly more patients were receiving other medications for concomitant conditions in specialist care. A total of 1416 patients (48%) did not meet DECLARE inclusion criteria, while 1561 (52%) patients met the criteria (Greece 41.05%, Italy 53.19%, Spain 51.35%). Conclusions: Significant differences were seen among patients initiating dapagliflozin in southern Europe. Our results suggest that dapagliflozin was being initiated at different stages of the disease according to the country and prescribing settings. Such geographic heterogeneity may have an impact upon effectiveness of dapagliflozin on glucose lowering, as well as cardiovascular and renal outcomes. © 2019, The Author(s).
ER -